Women's sexual and reproductive health pharmaceuticals
Strategic Profile
Evofem is executing a strategy to increase revenues and diversify its revenue stream through commercializing FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones forged for MENA and Sub-Saharan Africa. However, the company faces significant financial headwinds with minimal U.S. domestic sales and heavy leverage.
Cyborg Score Rationale
Q1 2026 net sales were $0.9 million, only slightly above $0.8 million a year earlier, while the company has total liabilities of $80.2 million, stockholders' deficit of $77.6 million, and cash of only $2.4 million against current liabilities of $78.8 million. The company faces going-concern risk and survival depends on successful international partnerships and capital restructuring.
Top Insights
(May 2026) Q1 2026 revenues of only $0.9M with net loss of $5.5M despite near-zero cash burn reduction efforts
(May 2026) Going-concern uncertainty with $77.6M stockholders' deficit and only $2.4M cash versus $78.8M current liabilities
(May 2026) International pivot strategy for MENA and Sub-Saharan Africa regions expected to generate non-dilutive capital in 2026
Company trades OTC after delisting compliance failures; product candidates face commercialization challenges in U.S. market